Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
Vogelmeier CF., Rabe KF., Bhatt SP., Hanania NA., Bafadhel M., Christenson SA., Papi A., Singh D., Laws E., Maloney J., Dakin P., Lu X., Bauer D., Bansal A., Robinson LB., Abdulai RM.